The direct and indirect health care costs associated with pulmonary arterial hypertension among commercially insured patients in the United States.

ABSTRACT: BACKGROUND: Pulmonary arterial hypertension (PAH) is a rare, progressive, and fatal disease associated with considerable overall clinical and economic burden. Although the direct health care costs of PAH have been well described, there are few data regarding indirect costs and productivity loss associated with PAH. Patient data were assessed until the earliest of death, end of full-time employment, end of continuous enrollment, or end of study period. OBJECTIVES: To update data on the direct burden and address the knowledge gap regarding the indirect burden associated with PAH. METHODS: This is a retrospective case-control study with prevalent and incident patients with PAH aged 18-64 years identified from the MarketScan Commercial and Health and Productivity managemen

SUBMITTER: Ogbomo A 

PROVIDER: S-EPMC10372985 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature